Litigation Details for Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2022)

« Back to Dashboard

Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2022)

Docket	1:22-cv-00639	Date Filed	2022-05-13
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997; 10,993,941; 11,026,931; 11,026,939; 11,040,029; 8,039,627; 8,357,697
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-13				External link to document

Neurocrine Biosciences v. Lupin Limited (1:22-cv-00639) Litigation Summary, Patent Issues, and Generic Launch Risk for Ingrezza (valbenazine)

Last updated: July 26, 2026

Neurocrine Biosciences, Inc. sued Lupin Limited in the US District Court for the District of Delaware in Neurocrine Biosciences, Inc. v. Lupin Limited, No. 1:22-cv-00639. The case is a branded-versus-generic patent infringement matter tied to Lupin’s effort to market a competing product for Ingrezza (valbenazine) after FDA approval. The litigation posture, including any asserted patent claims, Orange Book ties, and whether the suit resolved via dismissal, stipulation, settlement, or final judgment, determines the practical risk for a near-term Lupin entry and the scope of remaining exclusivity and “design-around” freedom for other ANDA filers.

What is the case background for Neurocrine Biosciences v. Lupin (1:22-cv-00639)?

Case name: Neurocrine Biosciences, Inc. v. Lupin Limited
Docket: 1:22-cv-00639
Court: US District Court for the District of Delaware
Caption parties: Neurocrine Biosciences, Inc. as plaintiff; Lupin Limited as defendant (Lupin entities may also appear depending on the docket caption)

Core dispute type

• Patent infringement litigation tied to generic competition for Ingrezza (valbenazine).
• Procedurally, these suits are typically connected to a Paragraph IV certification framework under the Hatch-Waxman Act (ANDA-based entry), with the asserted patents drawn from the FDA’s Orange Book listings for valbenazine products.

Business question the litigation answers

• Whether Lupin’s proposed valbenazine product will infringe one or more Orange Book-listed Neurocrine patents.
• Whether a generic entry can proceed without authorizing infringement.
• If infringement is found, the magnitude of injunction exposure and the timing of launch constraints.

Which patents did Neurocrine assert against Lupin in 1:22-cv-00639?

Actionable note: A precise infringement summary requires the asserted patent numbers and the specific claims asserted (claim chart level). Those details are not included in the information provided here, and a litigation-grade answer depends on exact patent identification.

What claims were at issue: method-of-use vs composition vs formulation?

A defensible litigation analysis requires mapping each asserted patent to:

• Patent type
  • Composition-of-matter (active ingredient salt, polymorph, hydrate, or specific chemical identity)
  • Formulation (dosage form composition, coatings, release mechanisms)
  • Method of use (treatment regimens, indications, dosing schedules)
  • Manufacturing methods (process claims, intermediates)
• Infringement theory
  • Direct infringement, inducement, or contributory infringement
• Generic “equivalence” posture
  • Whether Lupin attempted a design-around by changing salt form, polymorph, particle size, dosage formulation, or dosing regimen

Without the asserted patent list and claim specifics from the docket record, the litigation cannot be summarized at the level typically used by brand and generic counsel to estimate launch risk.

What is the litigation timeline for 1:22-cv-00639 (filing, amendments, hearings, rulings)?

A litigation summary for high-stakes business decisions requires:

• filing date
• service and answer deadlines
• amended complaints and counterclaims
• Markman dates or claim construction rulings
• dispositive motions (Rule 12/56)
• trial status and any final judgment
• any stay status tied to PTO proceedings (inter partes review), if relevant

These timing events are docket-specific and are not present in the supplied prompt.

How do Paragraph IV certifications typically drive the claims in Neurocrine v. Lupin?

In Hatch-Waxman valbenazine cases, Paragraph IV disputes usually hinge on:

• Orange Book-listed patents for the relevant NDA (or listed patents on the referenced drug)
• whether the generic filing triggers infringement of those patents
• whether the asserted patents are invalid, unenforceable, or not infringed

A litigation strategy review depends on knowing:

• which patents were certified as invalid or not infringed
• whether Lupin used a different version of valbenazine (for example, alternative salt form or formulation differences)
• whether the court adjudicated validity or infringement, or if the case ended before merits

What does the docket reveal about Lupin’s generic entry risk?

For business professionals, the generic launch risk is driven by three measurable outcomes:

1. Whether Neurocrine obtained an injunction (or a court-ordered launch block).
2. Whether any asserted patents were narrowed or invalidated, leaving the brand with fewer enforceable rights.
3. Whether the case ended via settlement, which often includes:
   • “no-approval”/“no-launch” commitments
   • design-around permission for specific claims
   • licensing of certain IP rights
   • staggered entry dates by dosage strength

A launch forecast cannot be made without settlement terms, case disposition, or a summary judgment record.

Has the case been stayed pending USPTO IPRs or other proceedings?

Many branded-versus-generic litigations are stayed pending:

• inter partes review of one or more asserted patents
• reexamination or related PTAB proceedings

Stay existence and scope are docket facts that directly affect the time to potential generic market entry. No stay information is included in the prompt.

What is the Orange Book status for Ingrezza valbenazine that is relevant to this dispute?

Orange Book status typically indicates:

• the listed patent(s) covering NDA-associated formulations and/or methods
• expiration dates for each listed patent
• the “orphan drug exclusivity” or other exclusivity periods, where applicable
• the patent-to-product mapping that defines what a Paragraph IV challenger targets

A litigation-grade answer requires listing the exact Orange Book patents at issue in this case. Those are not included here.

How does this case compare with other Ingrezza patent litigations involving challengers?

A competitive analysis depends on comparing:

• the asserted patent sets across cases
• the claim constructions and validity outcomes
• settlement structures across the portfolio of ANDA challengers

Without the asserted patent list and disposition, a direct comparison is not possible.

What is the strength of Neurocrine’s patent estate in valbenazine based on typical Ingrezza enforcement patterns?

A credible strength assessment requires:

• identification of the exact patents asserted in this case
• whether the asserted claims include composition/formulation/method claims
• whether courts previously upheld validity for similar claims

These inputs are missing from the prompt.

Which generic companies are most exposed to the same patent barriers in valbenazine?

Exposure mapping requires the Orange Book patents and the list of ANDA filers, which is not provided here.

What are the likely damages and remedies if infringement is found?

Typical remedies in Hatch-Waxman patent cases include:

• permanent injunctions for infringement of specific patents
• damages and, in some scenarios, ongoing royalties
• potential treble damages if willful infringement is pled and proven

A case-specific remedies assessment requires the procedural posture and claims adjudicated, which are not in the prompt.

Key Takeaways

• Neurocrine Biosciences v. Lupin Limited (1:22-cv-00639) is a US patent infringement litigation tied to generic competition for Ingrezza (valbenazine).
• The business impact depends on the asserted patent numbers and disposition (infringement findings, invalidity findings, injunctions, settlement, or dismissal).
• The supplied prompt does not contain the docket facts needed to produce a litigation-grade summary of:
  • asserted patents and claims
  • claim construction outcomes
  • timeline milestones
  • settlement terms or case disposition

FAQs

1. What typically triggers the filing of a Hatch-Waxman suit like Neurocrine v. Lupin?
2. How do Paragraph IV certifications affect the timing of generic valbenazine market entry?
3. What court events most influence launch risk in patent suits over branded CNS drugs?
4. How does an IPR stay change the practical litigation calendar for generic challengers?
5. What settlement terms most often appear in ANDA patent litigations for oral CNS drugs?

References

1. [No citable sources were provided in the prompt.]